Similar articles

• Which is the foreseeable clinical application of oxygen-carrying blood substitutes (fluorocarbons and hemoglobin solutions)? Which impact are they likely to have on the activity of blood services?

  [No authors listed] [No authors listed] Vox Sang. 1982 Feb;42(2):97-109. doi: 10.1159/000460856. Vox Sang. 1982. PMID: 7064434 No abstract available.
• The use of fluorocarbon emulsions in cancer radiotherapy.

  Guichard M. Guichard M. Radiother Oncol. 1991;20 Suppl 1:59-64. doi: 10.1016/0167-8140(91)90189-n. Radiother Oncol. 1991. PMID: 2020771 Review.
• Development and clinical application of perfluorochemical artificial blood.

  Ohyanagi H, Saitoh Y. Ohyanagi H, et al. Int J Artif Organs. 1986 Sep;9(5):363-8. Int J Artif Organs. 1986. PMID: 3781670
• Role of the perfluorocarbon Fluosol-DA in coronary angioplasty.

  Kerins DM. Kerins DM. Am J Med Sci. 1994 Mar;307(3):218-21. doi: 10.1097/00000441-199403000-00009. Am J Med Sci. 1994. PMID: 8160713 Review. No abstract available.
• Clinical experience with Fluosol-DA (20%) in the United States.

  Tremper KK, Levine EM, Waxman K. Tremper KK, et al. Int Anesthesiol Clin. 1985 Spring;23(1):185-97. doi: 10.1097/00004311-198502310-00017. Int Anesthesiol Clin. 1985. PMID: 3884514 Clinical Trial. No abstract available.